Menarini Pays $100 Million for China Rights to 4SC Cancer Drug

Menarini of Italy in-licensed China and Asia-Pacific rights to a proposed liver cancer treatment developed by Germany's 4SC AG for $100 million in upfront and milestone payments. Resminostat, 4SC's lead oncology compound, is an oral histone-deacetylase (HDAC) inhibitor currently in Phase II trials in Europe and Japan. According to 4SC, resminostat has a novel epigenetic mechanism of action that could be effective against several types of cancer, most likely in combination with other drugs. More details.... Stock Symbol: (F: VSC) Share this with colleagues: // //